DE69312297D1 - Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs - Google Patents

Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs

Info

Publication number
DE69312297D1
DE69312297D1 DE69312297T DE69312297T DE69312297D1 DE 69312297 D1 DE69312297 D1 DE 69312297D1 DE 69312297 T DE69312297 T DE 69312297T DE 69312297 T DE69312297 T DE 69312297T DE 69312297 D1 DE69312297 D1 DE 69312297D1
Authority
DE
Germany
Prior art keywords
treatment
pct
tumours
chlorophenyl
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69312297T
Other languages
English (en)
Other versions
DE69312297T2 (de
Inventor
Alan Thomas Langley Cou Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69312297D1 publication Critical patent/DE69312297D1/de
Publication of DE69312297T2 publication Critical patent/DE69312297T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69312297T 1992-08-07 1993-08-06 Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs Expired - Lifetime DE69312297T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929216859A GB9216859D0 (en) 1992-08-07 1992-08-07 Medicaments
PCT/GB1993/001669 WO1994003163A1 (en) 1992-08-07 1993-08-06 Use of 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone for the treatment of cancer

Publications (2)

Publication Number Publication Date
DE69312297D1 true DE69312297D1 (de) 1997-08-21
DE69312297T2 DE69312297T2 (de) 1997-10-30

Family

ID=10720039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69312297T Expired - Lifetime DE69312297T2 (de) 1992-08-07 1993-08-06 Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs

Country Status (11)

Country Link
US (1) US5567738A (de)
EP (1) EP0653936B1 (de)
JP (1) JPH07509710A (de)
KR (1) KR950702413A (de)
AT (1) ATE155343T1 (de)
AU (1) AU676687B2 (de)
CA (1) CA2141274A1 (de)
DE (1) DE69312297T2 (de)
ES (1) ES2105643T3 (de)
GB (1) GB9216859D0 (de)
WO (1) WO1994003163A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
WO2012153162A1 (en) 2011-05-12 2012-11-15 Lupin Limited Novel method for preparation of atovaquone
WO2013014486A1 (en) 2011-07-28 2013-01-31 Lupin Limited Improved synthesis of 2-(4-(4-chlorophenyl) cyclohex-1-enyl) -3, 4-dihydronaphthalen-1 (2h)-one; an intermediate for atovaquone
KR101990054B1 (ko) * 2017-04-25 2019-06-17 대구대학교 산학협력단 로손을 유효성분으로 포함하는 항암 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533648A (en) * 1949-03-05 1950-12-12 Joseph H Warburg Circular saw making
US3347742A (en) * 1965-05-28 1967-10-17 Merck & Co Inc 2-(4-cyclohexylcyclohexyl)-3-hydroxy-1, 4-naphthoquinone in controlling coccidiosis in poultry
US3367830A (en) * 1965-06-23 1968-02-06 Merck & Co Inc Controlling coccidiosis in poultry with 1,4-naphthoquinones
GB1141735A (en) * 1966-11-23 1969-01-29 Pfizer & Co C Pharmaceutical anti-tumor composition
US3655699A (en) * 1970-03-02 1972-04-11 Pfizer Analogues of lapachol as antitumor agents
GB1553424A (en) * 1976-02-10 1979-09-26 Wellcome Found Method of treating protozal diseases
JPS5492945A (en) * 1977-11-22 1979-07-23 Wellcome Found Naphthoquinone derivative
US4485116A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
US4485117A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
GB8310141D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Naphthoquinone derivatives
GB8310140D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Antiprotozoal agents
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
JP2804302B2 (ja) * 1988-08-16 1998-09-24 ザ ウエルカム フアウンデーション リミテッド 治療剤
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
DE68912262T2 (de) * 1988-10-07 1994-05-11 Sakai Chemical Industry Co Katalysatoren und Verfahren zur Denitrierung.

Also Published As

Publication number Publication date
DE69312297T2 (de) 1997-10-30
EP0653936A1 (de) 1995-05-24
KR950702413A (ko) 1995-07-29
US5567738A (en) 1996-10-22
WO1994003163A1 (en) 1994-02-17
AU676687B2 (en) 1997-03-20
ES2105643T3 (es) 1997-10-16
AU4722493A (en) 1994-03-03
CA2141274A1 (en) 1994-02-17
ATE155343T1 (de) 1997-08-15
EP0653936B1 (de) 1997-07-16
GB9216859D0 (en) 1992-09-23
JPH07509710A (ja) 1995-10-26

Similar Documents

Publication Publication Date Title
FI971951A0 (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
DE69312297D1 (de) Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs
DE69516110D1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
ATE190484T1 (de) Arzneimittel zur behandlung von durch babesia verursachten protozoeninfektionen
DE68916651D1 (de) Heilmittel zur behandlung von toxoplasmose.
ATE205399T1 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
FI950403A0 (fi) Neurosuojaavia yhdisteitä
DE60206280D1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
ATE107504T1 (de) Arzneimittel zur behandlung von kryptosporidiose.
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
GEP19970834B (en) 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
ATE172118T1 (de) Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose
DE69307197D1 (de) Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE60113895D1 (de) Verwendung von Tiludronsäure beim Geflügel zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von Osteoporose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition